Detalhe da pesquisa
1.
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Am J Hematol
; 99(4): 763-766, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38317312
2.
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
Br J Haematol
; 194(3): 604-612, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34212373
3.
Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
Br J Haematol
; 189(3): 469-474, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037516
4.
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.
Blood Adv
; 8(10): 2361-2372, 2024 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447114
5.
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Leukemia
; 36(7): 1879-1886, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35676453
6.
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
Leukemia
; 36(7): 1834-1842, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35614319
7.
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
Leukemia
; 34(8): 2113-2124, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32472084
8.
BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing.
Am J Hematol
; 89(10): 1016-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24984979
9.
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
J Cancer Res Clin Oncol
; 145(6): 1645-1650, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30941573
10.
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Leukemia
; 38(4): 893-897, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38472478
11.
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
Am J Hematol
; 86(3): 318-21, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21328429
12.
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients.
Leuk Lymphoma
; 62(5): 1239-1242, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33356699
13.
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.
Oncotarget
; 7(22): 33016-24, 2016 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-27145281
14.
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Am J Hematol
; 85(7): 525-8, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20575042
15.
Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
Mol Diagn Ther
; 16(4): 251-9, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22873741
16.
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Mol Diagn Ther
; 16(3): 163-6, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22489663
17.
A case of a novel PML/RARA short fusion transcript with truncated transcription variant 2 of the RARA gene.
Mol Diagn Ther
; 14(2): 113-7, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20359255
18.
Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
Exp Hematol
; 38(1): 20-6, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19837125
19.
CEBPA gene mutational status: a complete screening using high-resolution melt curve analysis.
Mol Diagn Ther
; 13(3): 195-200, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19650672
20.
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Exp Hematol
; 37(6): 659-72, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19463768